Prothena Unveils Promising Preclinical Results for TDP-43 CYTOPE in ALS Mouse Model

Reuters

Nov 20, 2025

Prothena Unveils Promising Preclinical Results for TDP-43 CYTOPE in ALS Mouse Model

Prothena Corporation plc has announced a scientific poster presentation for its TDP-43 CYTOPE® program at Neuroscience 2025, hosted by the Society for Neuroscience (SfN) in San Diego, California. The presentation, scheduled for November 19, 2025, will detail preclinical data on a cell-internalizing CYTOPE® targeting pTDP-43 in a mouse model of amyotrophic lateral sclerosis (ALS). According to Prothena, systemically-administered TDP-43 CYTOPE® demonstrated rapid brain distribution, efficient cytosolic internalization, and significant reduction of intracellular pTDP-43 pathology in preclinical models. The results from these studies will be presented at the upcoming conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prothena Corporation plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20251119275479) on November 19, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2584568975"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584568975\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584568975?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 05:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584568975","market":"nz","top_or_hot":-1,"title":"Prothena Unveils Promising Preclinical Results for TDP-43 CYTOPE in ALS Mouse Model","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Prothena Unveils Promising Preclinical Results for TDP-43 CYTOPE in ALS Mouse Model\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PRTA\">Prothena Corporation plc</a> has announced a scientific poster presentation for its TDP-43 CYTOPE® program at Neuroscience 2025, hosted by the Society for Neuroscience (SfN) in San Diego, California. The presentation, scheduled for November 19, 2025, will detail preclinical data on a cell-internalizing CYTOPE® targeting pTDP-43 in a mouse model of amyotrophic lateral sclerosis (ALS). According to Prothena, systemically-administered TDP-43 CYTOPE® demonstrated rapid brain distribution, efficient cytosolic internalization, and significant reduction of intracellular pTDP-43 pathology in preclinical models. The results from these studies will be presented at the upcoming conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prothena Corporation plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20251119275479) on November 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Prothena Unveils Promising Preclinical Results for TDP-43 CYTOPE in ALS Mouse Model</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProthena Unveils Promising Preclinical Results for TDP-43 CYTOPE in ALS Mouse Model\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-20 05:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Prothena Unveils Promising Preclinical Results for TDP-43 CYTOPE in ALS Mouse Model\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PRTA\">Prothena Corporation plc</a> has announced a scientific poster presentation for its TDP-43 CYTOPE® program at Neuroscience 2025, hosted by the Society for Neuroscience (SfN) in San Diego, California. The presentation, scheduled for November 19, 2025, will detail preclinical data on a cell-internalizing CYTOPE® targeting pTDP-43 in a mouse model of amyotrophic lateral sclerosis (ALS). According to Prothena, systemically-administered TDP-43 CYTOPE® demonstrated rapid brain distribution, efficient cytosolic internalization, and significant reduction of intracellular pTDP-43 pathology in preclinical models. The results from these studies will be presented at the upcoming conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prothena Corporation plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20251119275479) on November 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRTA","symbol_name":"Prothena Corporation plc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDLcb43wQ:1","article_id":"2584568975","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584568975","pubTimestamp":1763586384,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Prothena Corporation plc has announced a scientific poster presentation for its TDP-43 CYTOPE program at Neuroscience 2025, hosted by the Society for Neuroscience  in San Diego, California. The presentation, scheduled for November 19, 2025, will detail preclinical data on a cell-internalizing CYTOPE targeting pTDP-43 in a mouse model of amyotrophic lateral sclerosis . According to Prothena, systemically-administered TDP-43 CYTOPE demonstrated rapid brain distribution, efficient cytosolic internalization, and significant reduction of intracellular pTDP-43 pathology in preclinical models. The results from these studies will be presented at the upcoming conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prothena Corporation plc pu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRTA":"Prothena Corporation plc","BK4139":"生物科技"},"translate_title":"Prothena公布了ALS小鼠模型中TDP-43细胞表位的有希望的临床前结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRTA":0.9},"content_text":"Prothena Unveils Promising Preclinical Results for TDP-43 CYTOPE in ALS Mouse Model\n    \n\nProthena Corporation plc has announced a scientific poster presentation for its TDP-43 CYTOPE® program at Neuroscience 2025, hosted by the Society for Neuroscience (SfN) in San Diego, California. The presentation, scheduled for November 19, 2025, will detail preclinical data on a cell-internalizing CYTOPE® targeting pTDP-43 in a mouse model of amyotrophic lateral sclerosis (ALS). According to Prothena, systemically-administered TDP-43 CYTOPE® demonstrated rapid brain distribution, efficient cytosolic internalization, and significant reduction of intracellular pTDP-43 pathology in preclinical models. The results from these studies will be presented at the upcoming conference.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prothena Corporation plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20251119275479) on November 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}